MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ContraFect Corp Company Profile (NASDAQ:CFRX)

Consensus Ratings for ContraFect Corp (NASDAQ:CFRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.15 (78.20% upside)

Analysts' Ratings History for ContraFect Corp (NASDAQ:CFRX)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Roth CapitalDowngradeBuy -> Neutral$4.00 -> $3.30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Maxim GroupReiterated RatingBuy$8.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for ContraFect Corp (NASDAQ:CFRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016($0.25)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.23)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015($0.27)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/7/2015($0.23)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.15)($1.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for ContraFect Corp (NASDAQ:CFRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.26)($0.23)($0.25)
Q2 20162($0.25)($0.23)($0.24)
Q3 20162($0.28)($0.27)($0.28)
Q4 20162($0.29)($0.27)($0.28)
(Data provided by Zacks Investment Research)
Dividend History for ContraFect Corp (NASDAQ:CFRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ContraFect Corp (NASDAQ:CFRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/17/2015Daniel CoutoSVPSell2,872$3.81$10,942.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Daniel CoutoSVPSell2,867$4.23$12,127.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015Daniel CoutoSVPSell2,867$4.48$12,844.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Daniel CoutoSVPSell2,867$4.11$11,783.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2015Daniel CoutoSVPSell2,867$4.76$13,646.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Daniel CoutoSVPSell2,867$4.90$14,048.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Julia P GregoryCEOBuy11,778$4.61$54,296.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ContraFect Corp (NASDAQ:CFRX)
DateHeadline
06/27/16 01:30 PMCFRX: New PK/PD and Microbiologic Data Presented on CF-301 -
06/27/16 05:10 AMCONTRAFECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/21/16 06:29 AMContraFect Presents New CF-301 Data at ASM Microbe 2016 - [at noodls] - YONKERS, NY -- (Marketwired) -- 06/21/16 -- ContraFect Corporation(NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
06/21/16 06:01 AM7:01 am ContraFect announces 3 presentations of new data on CF-301 at ASM 2016 -
06/10/16 04:04 PMContraFect Corp. :CFRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/08/16 06:08 AMContraFect Announces Presentation of Data at ASM Microbe 2016 - [at noodls] - YONKERS, NY -- (Marketwired) -- 06/08/16 -- ContraFect Corporation(NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
06/01/16 06:23 AMContraFect to Present at Jefferies 2016 Healthcare Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 06/01/16 -- ContraFect Corporation(NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
05/17/16 11:45 AMCFRX: Phase 2 Trial of CF-301 in Bacteremia Patients to Commence in 4Q16 -
05/10/16 03:15 PMCONTRAFECT CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Ma -
05/10/16 06:28 AMContraFect Announces First Quarter 2016 Results - [at noodls] - YONKERS, NY -- (Marketwired) -- 05/10/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
05/10/16 06:07 AMQ1 2016 ContraFect Corp Earnings Release - Time Not Supplied -
05/03/16 06:10 AMContraFect Corporation to Announce First Quarter 2016 Results on May 10, 2016 - [at noodls] - YONKERS, NY -- (Marketwired) -- 05/03/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics ...
04/12/16 12:35 PMCFRX: CF-301 Phase 1 Results Presented at ECCMID Conference -
04/12/16 05:03 AMCONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers -
04/01/16 07:46 AMKeryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors - [at noodls] - BOSTON, April 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today ...
04/01/16 07:46 AMKeryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors - [at noodls] - BOSTON, April 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today ...
03/29/16 06:24 AMContraFect to Present CF-301 Phase 1 Trial Data at the 26th ECCMID Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 03/29/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
03/29/16 06:24 AMContraFect to Present CF-301 Phase 1 Trial Data at the 26th ECCMID Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 03/29/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
02/26/16 01:15 PMStocks With High Analyst Interest: The Spectranetics Corporation (NASDAQ:SPNC), Euronet Worldwide, Inc. (NASDAQ ... - RiversideGazette.com - Stocks With High Analyst Interest: The Spectranetics Corporation (NASDAQ:SPNC), Euronet Worldwide, Inc. (NASDAQ ...RiversideGazette.comShares of ContraFect Corporation (NASDAQ:CFRX) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $11.00 price target according to the covering analysts.
02/26/16 01:15 PMChanges To Broker Targets On ContraFect Corporation (CFRX) - Share Trading News - Changes To Broker Targets On ContraFect Corporation (CFRX)Share Trading NewsThe share price of ContraFect Corporation (CFRX) was down -4.52% during the last trading session, with a day high of 3.27. 18084 shares were traded on ContraFect Corporation's last session. The stock's 50 day moving average is 3.61 and its 200 day ...
02/02/16 06:00 AMContraFect to Present at 18th Annual BIO CEO and Investor Conference - [Marketwired] - ContraFect Corporation , a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced...
01/20/16 04:26 PMCONTRAFECT CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
01/05/16 06:38 AMContraFect to Present at 8th Annual Biotech Showcase Conference - [at noodls] - -- () -- -- (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious ...
12/16/15 03:30 PMCFRX: Phase 1 Study of CF-301 Complete with No Clinical Adverse Safety Signals Found; Increasing PT to $12 -
12/15/15 06:16 AMContraFect Corporation Concludes Phase 1 Study of CF-301 - [at noodls] - -- () -- -- (NASDAQ: CFRX)(NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant ...
12/08/15 12:17 PMCONTRAFECT CORP Financials -
11/30/15 03:55 PMContraFect to Present at 27th Annual Piper Jaffray Healthcare Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 11/30/15 -- ContraFect Corporation(NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products ...
11/18/15 01:00 PMCFRX: Warrant Exercise Brings in $9.6 Million; Data From Phase 1 Study of CF-301 in 1H2016… -
11/12/15 05:45 PMContraFect reports 3Q loss -
11/12/15 05:23 PMCONTRAFECT CORP Files SEC form 10-Q, Quarterly Report -
11/12/15 05:16 PMContraFect Corporation Announces Third Quarter 2015 Financial and Operating Results - [at noodls] - YONKERS, NY -- (Marketwired) -- 11/12/15 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) FDA Fast Track Designation Granted to CF-301, currently in Phase 1 clinical trials for Staph bacteremia, ...
About ContraFect Corp

ContraFect Corp logo

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CFRX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.89
  • 50 Day Moving Average: $2.81
  • 200 Day Moving Average: $3.49
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $79.43M
  • Current Quarter EPS Consensus Estimate: $-1.16 EPS
Additional Links:
ContraFect Corp (NASDAQ:CFRX) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha